Diclofenac for TMJ Disorders

Role of NSAIDs in TMJ Management

The American College of Rheumatology conditionally recommends diclofenac and other NSAIDs as brief, first-line pharmacological therapy for TMJ pain, with the goal of using them for the shortest duration possible while prioritizing non-pharmacological interventions that provide superior pain relief 1, 2
The American College of Rheumatology emphasizes that the initial NSAID trial should be brief due to potential adverse effects and limited efficacy unless inactive disease is achieved 1, 2

NSAIDs provide uncertain benefits for TMJ pain compared to the substantial pain reduction achieved with manual trigger point therapy and supervised jaw exercises 3, 4

The American College of Rheumatology recommends initiating manual trigger point therapy immediately, as it provides the largest pain reduction of any intervention 3, 4
The American College of Rheumatology suggests beginning supervised jaw exercises with stretching, which provides 1.5 times the minimally important difference in pain relief 3, 4, 5
Consider a brief trial of NSAIDs (diclofenac or other NSAID) for symptomatic relief, using the lowest effective dose for the shortest possible time 1, 2, 4

Never combine NSAIDs with opioids, as this increases harm without providing additional benefit 5
Do not rely solely on NSAIDs when manual trigger point therapy and jaw exercises provide superior pain relief with better safety profiles 3, 4
Avoid prolonged NSAID use, as the brief initial trial should be measured in weeks, not months, particularly given the potential for gastrointestinal complications 1, 2

For children with TMJ arthritis, NSAIDs are conditionally recommended as part of initial therapy, but rapid escalation to DMARDs is often appropriate given the destructive nature and high impact of TMJ arthritis on quality of life 7, 1, 2
Conventional synthetic DMARDs are strongly recommended for inadequate response to NSAIDs in juvenile TMJ arthritis 7, 1, 2
Biologic DMARDs are conditionally recommended after failure of NSAIDs and at least one conventional synthetic DMARD 1, 2